NanoVibronix (NSDQ:NAOV) yesterday released results from a study exploring the use of its PainShield device in treating patients with trigeminal neuralgia, touting improved pain relief and quality of life.
The PainShield is a device designed to treat pain in nerves, muscles and joints through the delivery of localized ultrasound, the Elmsford, N.Y.-based company said.
In the 59-patient double blinded, crossover trial, investigators examined the use of the device in treating individuals with unilateral trigeminal neuralgia using assessments on the Visual Analog Scale pain score as well as breakthrough medications per week. Breakthrough medications in the trial were used for chronic pain related to pre-existing trigeminal neuralgia conditions.
Results indicated that patients treated with the PainShield saw a 55.2% improvement from their baseline VAS scores after treatment, compared to only a 2.3% increase for patients in the control group. Patients treated with the PainShield also saw a 46.4% reduction in breakthrough pain medication, versus only 1.5% in the control group.
“We are very pleased to report the final results of our PainShield study for patients with Trigeminal Neuralgia. We saw a dramatic improvement in both pain scores and the use of pain medications such as opioids. We look forward to having these results published in a leading medical journal and aggressively marketing the device to physicians in order to help the millions of patients worldwide suffering from this painful and debilitating condition. Given the current opioid crisis, the fact we can help reduce dependence on medications, will also help save lives. This was a very challenging patient population and we look forward to conducting similar studies, where we believe we can replicate our success for other painful conditions,” CEO Brian Murphy said in a press release.
In December, NanoVibronix said that it inked a deal with the U.K.’s IMS Ultrasound to make it the exclusive U.K. distributor of its UroShield device, designed to prevent catheter-acquired urinary tract infections.